NASDAQ:IPHA Innate Pharma Q2 2026 Earnings Report $1.85 -0.02 (-0.86%) As of 12:34 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innate Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.29Beat/MissN/AOne Year Ago EPSN/AInnate Pharma Revenue ResultsActual RevenueN/AExpected Revenue$6.35 millionBeat/MissN/AYoY Revenue GrowthN/AInnate Pharma Announcement DetailsQuarterQ2 2026Date9/17/2026TimeBefore Market OpensConference Call DateThursday, September 17, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Innate Pharma Earnings HeadlinesInnate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business UpdateSeptember 10, 2026 | finance.yahoo.comInnate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 10, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 14 at 1:00 AM | Behind the Markets (Ad)Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement TranscriptAugust 14, 2026 | seekingalpha.comInnate Pharma Announces Conference Call and WebcastAugust 14, 2026 | businesswire.comInnate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary SharesAugust 13, 2026 | finanznachrichten.deSee More Innate Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email. Email Address About Innate PharmaInnate Pharma (NASDAQ:IPHA) SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments. The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca. In addition to monalizumab, Innate Pharma’s pipeline includes multiple early- to late-stage candidates such as IPH5201 (anti-TIM-4) and IPH6101 (anti-IL-1RAP), which aim to broaden therapeutic options across solid tumors and hematological malignancies. These assets reflect Innate Pharma’s commitment to advancing precision immunotherapies through strategic partnerships and rigorous clinical development. Since its inception, Innate Pharma has established a global footprint, conducting multi-center clinical trials across Europe and North America. The company’s research facilities in Marseille support a multidisciplinary team of scientists, clinicians and regulatory experts focused on biomarker-driven approaches. Through collaborations with major pharmaceutical companies, Innate Pharma leverages complementary expertise to accelerate the translation of its discovery efforts into the clinic. Led by a management team with deep experience in biotechnology product development, Innate Pharma maintains a strategic focus on unlocking the potential of innate immunity for cancer treatment. The company’s operations benefit from a robust intellectual property portfolio and a track record of forging alliances that enhance its capacity to deliver innovative oncology solutions to patients worldwide.View Innate Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundFabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked DownAmgen Drops 10% on a Trial It Didn't Even RunWhat Might it Take for D-Wave to Reset Its Course? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
